IP Library › Granted Patent US 12,553,029
Granted Patent B2
US 12,553,029 · App. 18/674,755 · Granted Feb 17, 2026

Treatment of NSCLC patients with tumor infiltrating lymphocyte therapies

Inventors: Maria Fardis (San Carlos, CA); Friedrich-Reinhard Graf Finck Von Finckenstein (San Carlos, CA)
Assignee: Iovance Biotherapeutics, Inc.
C12N5/0634A61K31/664A61K35/17A61K38/2013A61K40/10A61K40/11A61K40/24A61K40/33A61K40/35A61K40/42A61P35/00C07K16/2809C12N5/0635C12N5/0636C12N5/0646A61K2239/55C12N2501/2302C12N2501/515C12N2502/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,553,029
App. No.
18/674,755
Granted
Feb 17, 2026
Kind
B2
Abstract

The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody and/or anti-PD-L1 antibody and/or VEGF inhibitor, or wherein the NSCLC has a predetermined tumor proportion score (TPS).

Claims (20)

1 . A method of treating non-small cell lung cancer (NSCLC) in a patient in need thereof, the method comprising administering a therapeutically effective population of tumor infiltrating lymphocytes (TILs) to the patient, wherein the patient is refractory or resistant to an immune-checkpoint inhibitor (ICI) treatment, wherein the refractory or resistant NSCLC has been previously treated with an ICI and has progressed on or after the treatment with the ICI, and wherein the patient has a predetermined absence of one or more driver mutations, and wherein the one or more driver mutations comprise an EGFR mutation; and further wherein the TILs are administered as a single agent.

2 . The method of claim 1 , wherein the patient has a predetermined tumor proportion score (TPS) of PD-L1 of <1% prior to ICI treatment or TPS prior to ICI treatment is unknown, or a TPS score of PD-L1 of ≥1% prior to ICI treatment.

3 . The method of claim 1 , wherein the patient has a TPS of PD-L1 of <1% prior to ICI treatment or TPS prior to ICI treatment is unknown.

4 . The method of claim 1 , wherein the patient has a TPS of PD-L1 of 2 1% prior to ICI treatment.

5 . The method of claim 1 , wherein the therapeutically effective population of TILs is produced using a tumor sample from surgical resection.

6 . The method of claim 1 , wherein the therapeutically effective population of TILs is produced using a tumor sample from needle biopsy, core biopsy, or small biopsy.

7 . The method of claim 1 , wherein the one or more driver mutations further comprise one or more of an ALK-mutation, a c-ROS-mutation (ROS1-mutation), or a ROS1 fusion.

8 . The method of claim 1 , wherein the patient has a NSCLC that is not indicated for treatment by an EGFR inhibitor, a BRAF inhibitor, an ALK inhibitor, a c-Ros inhibitor, a RET inhibitor, an ERBB2 inhibitor, BRCA inhibitor, a MAP2K1 inhibitor, PIK3CA inhibitor, CDKN2A inhibitor, a PTEN inhibitor, an UMD inhibitor, an NRAS inhibitor, a KRAS inhibitor, an NF1 inhibitor, MET inhibitor a TP53 inhibitor, a CREBBP inhibitor, a KMT2C inhibitor, a KMT2D mutation, an ARID1A mutation, a RB1 inhibitor, an ATM inhibitor, a SETD2 inhibitor, a FLT3 inhibitor, a PTPN11 inhibitor, a FGFR1 inhibitor, an EP300 inhibitor, a MYC inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a FBXW7 inhibitor, a CCND3 inhibitor, and a GNA11 inhibitor.

9 . The method of claim 1 , wherein the NSCLC is refractory or resistant to treatment with an anti-PD-1 and/or anti-PD-L1 antibody, wherein the refractory or resistant NSCLC has been previously treated with an anti-PD-1 and/or anti-PD-L1 antibody and has progressed on or after the treatment with the anti-PD-1 and/or anti-PD-L1 antibody.

10 . The method of claim 1 , wherein the NSCLC is refractory or resistant to treatment with a chemotherapeutic agent, wherein the refractory or resistant NSCLC has been previously treated with a chemotherapeutic agent and has progressed on or after the treatment with the chemotherapeutic agent.

11 . The method of claim 1 , wherein the NSCLC is refractory or resistant to a VEGF-A inhibitor, wherein the refractory or resistant NSCLC has been previously treated with a VEGF-A inhibitor and has progressed on or after the treatment with the VEGF-A inhibitor.

12 . The method of claim 1 , wherein the NSCLC has been previously treated with an anti-PD-1 or an anti-PD-L1 antibody and has been previously treated with a chemotherapeutic agent.

13 . The method of claim 1 , wherein the NSCLC has been previously treated with an anti-PD-1 and/or anti-PD-L1 antibody and has been previously treated with a chemotherapeutic agent and/or a VEGF-A inhibitor.

14 . The method of claim 13 , wherein the NSCLC has progressed on concurrent or sequential front-line PD-1/PD-L1 inhibitor+chemotherapy±bevacizumab.

15 . The method of claim 1 , wherein the NSCLC has been previously treated with an anti-PD-1 and/or anti-PD-L1 antibody and has bulky disease at baseline.

16 . The method of claim 1 , wherein the NSCLC has been treated with a chemotherapeutic agent and has bulky disease at baseline.

17 . The method of claim 1 , wherein the refractory or resistant NSCLC has been previously treated with a chemotherapeutic agent but is not being currently treated with a chemotherapeutic agent and has bulky disease at baseline.

18 . The method of claim 1 , wherein the NSCLC has been treated with a chemotherapeutic agent and/or VEGF-A inhibitor but is not being currently treated with a chemotherapeutic agent and/or VEGF-A inhibitor and has bulky disease at baseline.

19 . The method of claim 1 , wherein the patient has one or more genomic alterations except for EGFR, ALK and ROS1.

20 . The method of claim 19 , wherein the patient has been treated with a targeted therapy in addition to ICI treatment and chemotherapy.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2026
From: FARDIS, MARIA; FINCKENSTEIN, FRIEDRICH GRAF
To: IOVANCE BIOTHERAPEUTICS, INC.
Reel/Frame 073431/0773 →
CHANGE OF NAME Recorded Jan 12, 2026
From: FINCKENSTEIN, FRIEDRICH GRAF
To: GRAF FINCK VON FINCKENSTEIN, FRIEDRICH-REINHARD
Reel/Frame 073431/0862 →
Continuity (5)
Continuation 18247877
Provisional Application 63146402 · Feb 5, 2021
Provisional Application 63127027 · Dec 17, 2020
Provisional Application 63088282 · Oct 6, 2020
Related Publication 20240368543A1 · Nov 7, 2024
References Cited (400)
US 4704692A · Ladner · 1987 [cited by applicant]
US 4766106A · Katre et al. · 1988 [cited by applicant]
US 4897355A · Eppstein et al. · 1990 [cited by applicant]
US 4902502A · Nitecki et al. · 1990 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5019034A · Weaver et al. · 1991 [cited by applicant]
US 5089261A · Nitecki et al. · 1992 [cited by applicant]
US 5126132A · Rosenberg · 1992 [cited by applicant]
US 5128257A · Baer · 1992 [cited by applicant]
US 5137817A · Busta et al. · 1992 [cited by applicant]
US 5173158A · Schmukler · 1992 [cited by applicant]
US 5206344A · Katre et al. · 1993 [cited by applicant]
US 5232856A · Firth · 1993 [cited by applicant]
US 5273525A · Hofmann · 1993 [cited by applicant]
US 5279833A · Rose · 1994 [cited by applicant]
US 5304120A · Crandell et al. · 1994 [cited by applicant]
US 5318514A · Hofmann · 1994 [cited by applicant]
US 5443983A · Ochoa et al. · 1995 [cited by applicant]
US 5459127A · Felgner et al. · 1995 [cited by applicant]
US 5593875A · Wurm et al. · 1997 [cited by applicant]
US 5631237A · Dzau et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5714350A · Co et al. · 1998 [cited by applicant]
US 5739277A · Presta et al. · 1998 [cited by applicant]
US 5766902A · Craig et al. · 1998 [cited by applicant]
US 5811097A · Allison et al. · 1998 [cited by applicant]
US 5824778A · Ishikawa et al. · 1998 [cited by applicant]
US 5834250A · Wells et al. · 1998 [cited by applicant]
US 5855887A · Allison et al. · 1999 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5898031A · Crooke · 1999 [cited by applicant]
US 5908635A · Thierry · 1999 [cited by applicant]
US 5928893A · Kang et al. · 1999 [cited by applicant]
US 5955365A · Szoka, Jr. et al. · 1999 [cited by applicant]
US 5976567A · Wheeler et al. · 1999 [cited by applicant]
US 5977318A · Linsley et al. · 1999 [cited by applicant]
US 6010613A · Walters et al. · 2000 [cited by applicant]
US 6025337A · Truong et al. · 2000 [cited by applicant]
US 6051227A · Allison et al. · 2000 [cited by applicant]
US 6056938A · Unger et al. · 2000 [cited by applicant]
US 6078490A · Walters · 2000 [cited by applicant]
US 6096871A · Presta et al. · 2000 [cited by applicant]
US 6100071A · Davis-Smyth et al. · 2000 [cited by applicant]
US 6107094A · Crooke · 2000 [cited by applicant]
US 6110490A · Thierry · 2000 [cited by applicant]
US 6121022A · Presta et al. · 2000 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6207156B1 · Kuchroo et al. · 2001 [cited by applicant]
US 6210669B1 · Aruffo et al. · 2001 [cited by applicant]
US 6242195B1 · Idusogie et al. · 2001 [cited by applicant]
US 6277375B1 · Ward · 2001 [cited by applicant]
US 6303121B1 · Kwon · 2001 [cited by applicant]
US 6350861B1 · Co et al. · 2002 [cited by applicant]
US 6352694B1 · June et al. · 2002 [cited by applicant]
US 6362325B1 · Kwon · 2002 [cited by applicant]
US 6375929B1 · Thomas, Jr. et al. · 2002 [cited by applicant]
US 6410517B1 · Truong et al. · 2002 [cited by applicant]
US 6475994B2 · Tomalia et al. · 2002 [cited by applicant]
US 6479626B1 · Kim et al. · 2002 [cited by applicant]
US 6489458B2 · Hackett et al. · 2002 [cited by applicant]
US 6506559B1 · Fire et al. · 2003 [cited by applicant]
US 6528624B1 · Idusogie et al. · 2003 [cited by applicant]
US 6534055B1 · June et al. · 2003 [cited by applicant]
US 6534261B1 · Cox, III et al. · 2003 [cited by applicant]
US 6534484B1 · Wheeler et al. · 2003 [cited by applicant]
US 6538124B1 · Idusogie et al. · 2003 [cited by applicant]
US 6569997B1 · Kwon · 2003 [cited by applicant]
US 6607882B1 · Cox, III et al. · 2003 [cited by applicant]
US 6627442B1 · Humeau et al. · 2003 [cited by applicant]
US 6682736B1 · Hanson et al. · 2004 [cited by applicant]
US 6706289B2 · Lewis et al. · 2004 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6746838B1 · Choo et al. · 2004 [cited by applicant]
US 6794136B1 · Eisenberg et al. · 2004 [cited by applicant]
US 6821505B2 · Ward · 2004 [cited by applicant]
US 6824978B1 · Cox, III et al. · 2004 [cited by applicant]
US 6866997B1 · Choo et al. · 2005 [cited by applicant]
US 6867041B2 · Berenson et al. · 2005 [cited by applicant]
US 6884879B1 · Baca et al. · 2005 [cited by applicant]
US 6887466B2 · June et al. · 2005 [cited by applicant]
US 6887673B2 · Kunkel et al. · 2005 [cited by applicant]
US 6903185B2 · Kim et al. · 2005 [cited by applicant]
US 6905680B2 · June et al. · 2005 [cited by applicant]
US 6905681B1 · June et al. · 2005 [cited by applicant]
US 6905685B2 · Kwon · 2005 [cited by applicant]
US 6933113B2 · Case · 2005 [cited by applicant]
US 6974863B2 · Kwon · 2005 [cited by applicant]
US 6979539B2 · Cox, III et al. · 2005 [cited by applicant]
US 6984720B1 · Korman et al. · 2006 [cited by applicant]
US 6998253B1 · Presta et al. · 2006 [cited by applicant]
US 7013219B2 · Case et al. · 2006 [cited by applicant]
US 7030215B2 · Liu et al. · 2006 [cited by applicant]
US 7056704B2 · Tuschl et al. · 2006 [cited by applicant]
US 7060269B1 · Baca et al. · 2006 [cited by applicant]
US 7078196B2 · Tuschl et al. · 2006 [cited by applicant]
US 7083784B2 · Dall'Acqua et al. · 2006 [cited by applicant]
US 7109003B2 · Hanson et al. · 2006 [cited by applicant]
US 7132281B2 · Hanson et al. · 2006 [cited by applicant]
US 7144575B2 · June et al. · 2006 [cited by applicant]
US 7148342B2 · Tolentino et al. · 2006 [cited by applicant]
US 7169901B2 · Baca et al. · 2007 [cited by applicant]
US 7175843B2 · June et al. · 2007 [cited by applicant]
US 7189705B2 · Lam et al. · 2007 [cited by applicant]
US 7214493B2 · Kunkel et al. · 2007 [cited by applicant]
US 7220719B2 · Case et al. · 2007 [cited by applicant]
US 7227004B2 · Kim · 2007 [cited by applicant]
US 7232566B2 · June et al. · 2007 [cited by applicant]
US 7241573B2 · Choo et al. · 2007 [cited by applicant]
US 7241574B2 · Choo et al. · 2007 [cited by applicant]
US 7282564B2 · Mello et al. · 2007 [cited by applicant]
US 7288638B2 · Jure-Kunkel et al. · 2007 [cited by applicant]
US 7297334B2 · Baca et al. · 2007 [cited by applicant]
US 7432249B2 · Crooke · 2008 [cited by applicant]
US 7432250B2 · Crooke · 2008 [cited by applicant]
US 7479269B2 · June et al. · 2009 [cited by applicant]
US 7504101B2 · Weinberg · 2009 [cited by applicant]
US 7538095B2 · Fire et al. · 2009 [cited by applicant]
US 7550140B2 · Bakker et al. · 2009 [cited by applicant]
US 7560438B2 · Fire et al. · 2009 [cited by applicant]
US 7572631B2 · Berenson et al. · 2009 [cited by applicant]
US 7585849B2 · Liu et al. · 2009 [cited by applicant]
US 7595376B2 · Kim et al. · 2009 [cited by applicant]
US 7622444B2 · Weinberg · 2009 [cited by applicant]
US 7687070B2 · Gebeyehu et al. · 2010 [cited by applicant]
US 7696175B2 · Epstein et al. · 2010 [cited by applicant]
US 7943743B2 · Korman et al. · 2011 [cited by applicant]
US 7951365B2 · Winqvist et al. · 2011 [cited by applicant]
US 7960515B2 · Min et al. · 2011 [cited by applicant]
US 8007785B2 · Winqvist et al. · 2011 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8034334B2 · Dudley et al. · 2011 [cited by applicant]
US 8133983B2 · Bakker et al. · 2012 [cited by applicant]
US 8168757B2 · Finnefrock et al. · 2012 [cited by applicant]
US 8206702B2 · Winqvist et al. · 2012 [cited by applicant]
US 8211424B2 · Winqvist et al. · 2012 [cited by applicant]
US 8211425B2 · Winqvist et al. · 2012 [cited by applicant]
US 8217149B2 · Irving et al. · 2012 [cited by applicant]
US 8236930B2 · Min et al. · 2012 [cited by applicant]
US 8287856B2 · Li et al. · 2012 [cited by applicant]
US 8287857B2 · Dudley et al. · 2012 [cited by applicant]
US 8337850B2 · Ahrens et al. · 2012 [cited by applicant]
US 8354509B2 · Carven et al. · 2013 [cited by applicant]
US 8383099B2 · Dudley et al. · 2013 [cited by applicant]
US 8450460B2 · Hill et al. · 2013 [cited by applicant]
US 8580247B2 · Li et al. · 2013 [cited by applicant]
US 8586526B2 · Gregory et al. · 2013 [cited by applicant]
US 8617884B2 · Berenson et al. · 2013 [cited by applicant]
US 8686119B2 · Rotem-Yehudar et al. · 2014 [cited by applicant]
US 8697359B1 · Zhang · 2014 [cited by applicant]
US 8735553B1 · Li et al. · 2014 [cited by applicant]
US 8771945B1 · Zhang · 2014 [cited by applicant]
US 8779108B2 · Queva et al. · 2014 [cited by applicant]
US 8809050B2 · Vera et al. · 2014 [cited by applicant]
US 8821867B2 · Ahrens et al. · 2014 [cited by applicant]
US 8865406B2 · Zhang et al. · 2014 [cited by applicant]
US 8871445B2 · Cong et al. · 2014 [cited by applicant]
US 8895308B1 · Zhang et al. · 2014 [cited by applicant]
US 8906616B2 · Zhang et al. · 2014 [cited by applicant]
US 8907053B2 · Sasikumar et al. · 2014 [cited by applicant]
US 8921519B2 · Hill et al. · 2014 [cited by applicant]
US 8932814B2 · Cong et al. · 2015 [cited by applicant]
US 8945839B2 · Zhang · 2015 [cited by applicant]
US 8956860B2 · Vera et al. · 2015 [cited by applicant]
US 8962804B2 · Williams et al. · 2015 [cited by applicant]
US 8993233B2 · Zhang et al. · 2015 [cited by applicant]
US 8999641B2 · Zhang et al. · 2015 [cited by applicant]
US 9006399B2 · Liu et al. · 2015 [cited by applicant]
US 9018230B2 · Mano et al. · 2015 [cited by applicant]
US 9028824B2 · Min et al. · 2015 [cited by applicant]
US 9044442B2 · Sasikumar et al. · 2015 [cited by applicant]
US 9074185B2 · Dudley et al. · 2015 [cited by applicant]
US 9080171B2 · Khvorova et al. · 2015 [cited by applicant]
US 9096642B2 · Sasikumar et al. · 2015 [cited by applicant]
US 9163085B2 · Liu et al. · 2015 [cited by applicant]
US 9340599B2 · Hill et al. · 2016 [cited by applicant]
US 9359420B2 · Hill et al. · 2016 [cited by applicant]
US 9458508B2 · Morris et al. · 2016 [cited by applicant]
US 9468678B2 · Ahrens et al. · 2016 [cited by applicant]
US 9476028B2 · Karlsson-Parra et al. · 2016 [cited by applicant]
US 9528088B2 · Berenson et al. · 2016 [cited by applicant]
US 9687510B2 · Borrello et al. · 2017 [cited by applicant]
US 9777261B2 · Kim et al. · 2017 [cited by applicant]
US 9790490B2 · Zhang et al. · 2017 [cited by applicant]
US 9792403B2 · Sun et al. · 2017 [cited by applicant]
US 9844569B2 · Gros et al. · 2017 [cited by applicant]
US 9914783B1 · Afar et al. · 2018 [cited by applicant]
US 10087464B2 · Hayes et al. · 2018 [cited by applicant]
US 10130659B2 · Wardell · 2018 [cited by applicant]
US 10144779B2 · Van Dijk et al. · 2018 [cited by applicant]
US 10155945B2 · Knopov · 2018 [cited by applicant]
US 10183979B2 · Alvarez et al. · 2019 [cited by applicant]
US 10363273B2 · Wardell · 2019 [cited by applicant]
US 10517894B2 · Frank · 2019 [cited by applicant]
US 10537595B2 · Wardell · 2020 [cited by applicant]
US 10633654B2 · Pavco et al. · 2020 [cited by applicant]
US 10653723B1 · Wardell · 2020 [cited by applicant]
US 10905718B2 · Wardell · 2021 [cited by applicant]
US 10913948B2 · Khvorova · 2021 [cited by applicant]
US 10918666B2 · Wardell · 2021 [cited by applicant]
US 10925900B2 · Wardell et al. · 2021 [cited by applicant]
US 10933094B2 · Wardell · 2021 [cited by applicant]
US 10946044B2 · Wardell · 2021 [cited by applicant]
US 10946045B2 · Wardell · 2021 [cited by applicant]
US 10953046B2 · Wardell · 2021 [cited by applicant]
US 10953047B2 · Wardell · 2021 [cited by applicant]
US 11013770B1 · Wardell · 2021 [cited by applicant]
US 11026974B2 · Frank · 2021 [cited by applicant]
US 11168303B2 · Wardell · 2021 [cited by applicant]
US 11168304B2 · Wardell · 2021 [cited by applicant]
US 11220670B2 · Simpson-Abelson · 2022 [cited by applicant]
US 11254913B1 · Wardell · 2022 [cited by applicant]
US 11293009B2 · Simpson-Abelson · 2022 [cited by applicant]
US 11351198B2 · Frank · 2022 [cited by applicant]
US 11357841B2 · Ritthipichai · 2022 [cited by applicant]
US 11401507B2 · Simpson-Abelson · 2022 [cited by applicant]
US 11433097B2 · Fardis · 2022 [cited by applicant]
US 11517592B1 · Wardell · 2022 [cited by applicant]
US 11529372B1 · Wardell · 2022 [cited by applicant]
US 11541077B2 · Wardell · 2023 [cited by applicant]
US 11631483B2 · Brooks · 2023 [cited by applicant]
US 11713446B2 · Chartier-Courtaud · 2023 [cited by applicant]
US 11819517B2 · Wardell · 2023 [cited by applicant]
US 20020039581A1 · Carreno et al. · 2002 [cited by applicant]
US 20020076747A1 · Price et al. · 2002 [cited by applicant]
US 20020086014A1 · Korman et al. · 2002 [cited by applicant]
US 20030051263A1 · Fire et al. · 2003 [cited by applicant]
US 20030055020A1 · Fire et al. · 2003 [cited by applicant]
US 20030056235A1 · Fire et al. · 2003 [cited by applicant]
US 20040110704A1 · Yamane et al. · 2004 [cited by applicant]
US 20040265839A1 · Mello et al. · 2004 [cited by applicant]
US 20050095244A1 · Jure-Kunkel et al. · 2005 [cited by applicant]
US 20050100913A1 · Mello et al. · 2005 [cited by applicant]
US 20050106717A1 · Wilson et al. · 2005 [cited by applicant]
US 20050201994A1 · Korman et al. · 2005 [cited by applicant]
US 20060024798A1 · Mello et al. · 2006 [cited by applicant]
US 20080050342A1 · Fire et al. · 2008 [cited by applicant]
US 20080055443A1 · Okamoto et al. · 2008 [cited by applicant]
US 20080081373A1 · Fire et al. · 2008 [cited by applicant]
US 20080248576A1 · Fire et al. · 2008 [cited by applicant]
US 20090028857A1 · Li et al. · 2009 [cited by applicant]
US 20090131360A1 · Woolf et al. · 2009 [cited by applicant]
US 20100136030A1 · Salah-Eddine et al. · 2010 [cited by applicant]
US 20100143918A1 · Guo et al. · 2010 [cited by applicant]
US 20100203056A1 · Irving et al. · 2010 [cited by applicant]
US 20100221737A1 · Gu et al. · 2010 [cited by applicant]
US 20100266617A1 · Carven et al. · 2010 [cited by applicant]
US 20100285013A1 · Li et al. · 2010 [cited by applicant]
US 20110008369A1 · Finnefrock et al. · 2011 [cited by applicant]
US 20110027218A1 · Hill et al. · 2011 [cited by applicant]
US 20110039914A1 · Pavco et al. · 2011 [cited by applicant]
US 20110052530A1 · Dudley et al. · 2011 [cited by applicant]
US 20110111494A1 · Hill et al. · 2011 [cited by applicant]
US 20110136228A1 · Vera et al. · 2011 [cited by applicant]
US 20110201118A1 · Yang et al. · 2011 [cited by applicant]
US 20120244133A1 · Rosenberg et al. · 2012 [cited by applicant]
US 20130022600A1 · Li et al. · 2013 [cited by applicant]
US 20130034559A1 · Queva et al. · 2013 [cited by applicant]
US 20130045200A1 · Irving et al. · 2013 [cited by applicant]
US 20130045201A1 · Irving et al. · 2013 [cited by applicant]
US 20130045202A1 · Irving et al. · 2013 [cited by applicant]
US 20130102075A1 · Vera et al. · 2013 [cited by applicant]
US 20130108651A1 · Carven et al. · 2013 [cited by applicant]
US 20130109843A1 · Carven et al. · 2013 [cited by applicant]
US 20130115617A1 · Wilson · 2013 [cited by applicant]
US 20130117869A1 · Duchateau et al. · 2013 [cited by applicant]
US 20130131141A1 · Khvorova et al. · 2013 [cited by applicant]
US 20130131142A1 · Khvorova et al. · 2013 [cited by applicant]
US 20130315884A1 · Galetto et al. · 2013 [cited by applicant]
US 20140227237A1 · June et al. · 2014 [cited by applicant]
US 20140294898A1 · Miller et al. · 2014 [cited by applicant]
US 20140295426A1 · Albelda et al. · 2014 [cited by applicant]
US 20140328791A1 · Bossard et al. · 2014 [cited by applicant]
US 20140341917A1 · Nastri et al. · 2014 [cited by applicant]
US 20140377284A1 · Simons et al. · 2014 [cited by applicant]
US 20140377739A1 · Welch et al. · 2014 [cited by applicant]
US 20150056193A1 · Crosby et al. · 2015 [cited by applicant]
US 20150073024A1 · Sasikumar et al. · 2015 [cited by applicant]
US 20150073042A1 · Sasikumar et al. · 2015 [cited by applicant]
US 20150087581A1 · Sasikumar et al. · 2015 [cited by applicant]
US 20150110734A1 · Hill et al. · 2015 [cited by applicant]
US 20150125491A1 · Sasikumar et al. · 2015 [cited by applicant]
US 20150126709A1 · Hill et al. · 2015 [cited by applicant]
US 20150126710A1 · Hill et al. · 2015 [cited by applicant]
US 20150132288A1 · Simons et al. · 2015 [cited by applicant]
US 20150175966A1 · Vera et al. · 2015 [cited by applicant]
US 20150190506A1 · Cheung et al. · 2015 [cited by applicant]
US 20150203871A1 · Juillerat et al. · 2015 [cited by applicant]
US 20150320798A1 · Borrello et al. · 2015 [cited by applicant]
US 20160010058A1 · Gros et al. · 2016 [cited by applicant]
US 20160120906A1 · Galetto et al. · 2016 [cited by applicant]
US 20160208216A1 · Vera et al. · 2016 [cited by applicant]
US 20160215262A1 · Powell · 2016 [cited by applicant]
US 20160304873A1 · Wolfson et al. · 2016 [cited by applicant]
US 20170044496A1 · Sarnaik et al. · 2017 [cited by applicant]
US 20170081635A1 · Sarnaik et al. · 2017 [cited by applicant]
US 20170107490A1 · Maeurer · 2017 [cited by applicant]
US 20170114321A1 · Berenson et al. · 2017 [cited by applicant]
US 20170152478A1 · Rosenberg et al. · 2017 [cited by applicant]
US 20170258838A1 · Borrello et al. · 2017 [cited by applicant]
US 20180127715A1 · Veerapathran et al. · 2018 [cited by applicant]
US 20180148690A1 · Gros et al. · 2018 [cited by applicant]
US 20180187150A1 · De Larichaudy · 2018 [cited by applicant]
US 20180207201A1 · Wardell et al. · 2018 [cited by applicant]
US 20180228841A1 · Frank et al. · 2018 [cited by applicant]
US 20180280436A1 · Wardell et al. · 2018 [cited by applicant]
US 20180282694A1 · Wardell et al. · 2018 [cited by applicant]
US 20180363066A1 · Chalmers et al. · 2018 [cited by applicant]
US 20190000070A1 · De Larichaudy et al. · 2019 [cited by applicant]
US 20190002546A1 · Li et al. · 2019 [cited by applicant]
US 20190048096A1 · Hermann et al. · 2019 [cited by applicant]
US 20190048341A1 · Cardia et al. · 2019 [cited by applicant]
US 20190062706A1 · Almaasbak et al. · 2019 [cited by applicant]
US 20190136186A1 · Germeroth et al. · 2019 [cited by applicant]
US 20190201334A1 · Hakim et al. · 2019 [cited by applicant]
US 20190211337A1 · Khvorova et al. · 2019 [cited by applicant]
US 20190275133A1 · Charych et al. · 2019 [cited by applicant]
US 20190298801A1 · Kerwin et al. · 2019 [cited by applicant]
US 20190307796A1 · Delgoffe · 2019 [cited by applicant]
US 20190343918A1 · Graham et al. · 2019 [cited by applicant]
US 20200024350A1 · Van Dijk et al. · 2020 [cited by applicant]
US 20200121719A1 · Lotze et al. · 2020 [cited by applicant]
US 20200181220A1 · Ptacin et al. · 2020 [cited by applicant]
US 20200223907A1 · Balakrishnan et al. · 2020 [cited by applicant]
US 20200270334A1 · Deane et al. · 2020 [cited by applicant]
US 20200299644A1 · Frank et al. · 2020 [cited by applicant]
US 20200330601A1 · Ptacin et al. · 2020 [cited by applicant]
US 20200347350A1 · Karyampudi et al. · 2020 [cited by applicant]
US 20210038684A1 · Losey et al. · 2021 [cited by applicant]
CN 102816734A · 2012 [cited by applicant]
CN 106244538A · 2016 [cited by applicant]
CN 106591232A · 2017 [cited by applicant]
CN 107384867A · 2017 [cited by applicant]
EP 0154316B1 · 1989 [cited by applicant]
EP 0401384A1 · 1990 [cited by applicant]
EP 0404097B1 · 1996 [cited by applicant]
EP 0672141B1 · 2003 [cited by applicant]
EP 0928290B1 · 2005 [cited by applicant]
EP 1212422B1 · 2007 [cited by applicant]
EP 1309726B1 · 2009 [cited by applicant]
EP 1539929B1 · 2013 [cited by applicant]
EP 1176195B1 · 2013 [cited by applicant]
EP 2925329A1 · 2015 [cited by applicant]
EP 3188740A1 · 2017 [cited by applicant]
EP 3365434A1 · 2018 [cited by applicant]
EP 3368659A1 · 2018 [cited by applicant]
EP 3487990A1 · 2019 [cited by applicant]
JP 2022512915A · 2022 [cited by applicant]
JP 2023544199A · 2023 [cited by applicant]
WO WO88007089 · 1988 [cited by applicant]
WO WO93011161 · 1993 [cited by applicant]
WO WO95012673 · 1995 [cited by applicant]
WO WO95021925 · 1995 [cited by applicant]
WO WO96014339 · 1996 [cited by applicant]
WO WO96040915 · 1996 [cited by applicant]
WO WO97020574 · 1997 [cited by applicant]
WO WO98005787 · 1998 [cited by applicant]
WO WO98023289 · 1998 [cited by applicant]
WO WO98030679 · 1998 [cited by applicant]
WO WO98042752 · 1998 [cited by applicant]
WO WO99032619 · 1999 [cited by applicant]
WO WO99051642 · 1999 [cited by applicant]
WO WO99054342 · 1999 [cited by applicant]
WO WO99058572 · 1999 [cited by applicant]
WO WO00009560 · 2000 [cited by applicant]
WO WO00032767 · 2000 [cited by applicant]
WO WO00037504 · 2000 [cited by applicant]
WO WO00042072 · 2000 [cited by applicant]
WO WO01014424 · 2001 [cited by applicant]
WO WO01029058 · 2001 [cited by applicant]
WO WO200244215A2 · 2002 [cited by applicant]
WO WO2002060919A2 · 2002 [cited by applicant]
WO WO2003035835A2 · 2003 [cited by applicant]
WO WO2003074569A2 · 2003 [cited by applicant]
WO WO2003086459A1 · 2003 [cited by applicant]
WO WO2004016750A2 · 2004 [cited by applicant]
WO WO2004029207A2 · 2004 [cited by applicant]
WO WO2004035607A2 · 2004 [cited by applicant]
WO WO2004035752A2 · 2004 [cited by applicant]
WO WO2004031370A1 · 2004 [cited by applicant]
WO WO2004063351A2 · 2004 [cited by applicant]
WO WO2004074455A2 · 2004 [cited by applicant]
WO WO2004081021A2 · 2004 [cited by applicant]
WO WO2005040217A2 · 2004 [cited by applicant]
WO WO2004099249A2 · 2004 [cited by applicant]
WO WO2005012359A2 · 2005 [cited by applicant]
WO WO2005070963A1 · 2005 [cited by applicant]
WO WO2005077981A2 · 2005 [cited by applicant]
WO WO2005092380A2 · 2005 [cited by applicant]
WO WO2005092925A2 · 2005 [cited by applicant]
WO WO2005123780A2 · 2005 [cited by applicant]
WO WO2006009649A2 · 2006 [cited by applicant]
WO WO2006012168A2 · 2006 [cited by applicant]
WO WO2006019447A1 · 2006 [cited by applicant]
WO WO2006029219A2 · 2006 [cited by applicant]
WO WO2006047350A2 · 2006 [cited by applicant]
WO WO2006085967A2 · 2006 [cited by applicant]
WO WO2006121168A2 · 2006 [cited by applicant]
WO WO2006121810A2 · 2006 [cited by applicant]
WO WO2007067959A2 · 2007 [cited by applicant]
WO WO20070123737A2 · 2007 [cited by applicant]